Plaque · people with stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Denture plaque · people with stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · people with multiple sclerosis
It is very uncertain whether polyunsaturated fatty acid (PUFA) changes relapse(assessed as number of participants experiencing relapse) compared with monounsaturated fatty acid (MUFA) (very low certainty).
1 finding from 1 review
SAEs · people with multiple sclerosis
Omega‐3 showed no clear difference in SAEs (assessed as number of participants experiencing a SAE) compared with omega‐6 (low certainty).
1 finding from 1 review
Relapse · people with multiple sclerosis
Antioxidant showed no clear difference in relapse(assessed as number of participants experiencing relapse) compared with placebo (low certainty).
1 finding from 1 review
Change in validated disability scale ( · people with multiple sclerosis
1 finding from 1 review
Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis
Antioxidant showed no clear difference in global impression of deterioration (investigator defined global… compared with placebo (low certainty).
1 finding from 1 review
Number of participants with gadolinium‐enhancing T1 lesions on MRI · people with multiple sclerosis
It is very uncertain whether antioxidant changes MRI activity(assessed as number of participants with… compared with placebo (very low certainty).
1 finding from 1 review
SAEs · people with multiple sclerosis
Antioxidant showed no clear difference in SAEs (assessed as number of participants experiencing a SAE) compared with placebo (low certainty).
1 finding from 1 review
Change in validated disability scale ( · people with multiple sclerosis
1 finding from 1 review
Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis
Polyunsaturated fatty acid (PUFA) showed no clear difference in global impression of deterioration (investigator defined global… compared with monounsaturated fatty acid (MUFA) (low certainty).
1 finding from 1 review
MRI activity ‐ not measured · people with multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · people with multiple sclerosis
1 finding from 1 review
Relapse · people with multiple sclerosis
Omega‐3 showed no clear difference in relapse(assessed as number of participants experiencing relapse) compared with omega‐6 (low certainty).
1 finding from 1 review
Change in validated disability scale ( · people with multiple sclerosis
1 finding from 1 review
Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis
Omega‐3 showed no clear difference in global impression of deterioration (investigator defined global… compared with omega‐6 (moderate certainty).
1 finding from 1 review
MRI activity(assessed by new gadolinium‐enhancing lesions) · people with multiple sclerosis
1 finding from 1 review
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Azithromycin (500 mg 20 ‐ 28 days) probably leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (15 ‐ 20 mg/kg/d (moderate certainty).
1 finding from 1 review
Adverse effects · People with American cutaneous and mucocutaneous leishmaniasis
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous and mucocutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found